Related Experiment Video
Updated: Dec 22, 2025

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
Published on: May 17, 2024
Highlights of the 2018 Chinese hypertension guidelines
1Department of Cardiology, Peking University People's Hospital, Beijing, 100044 China.
Insights
The new Chinese hypertension guidelines maintain the 140/90 mmHg diagnosis threshold and recommend a risk-based treatment algorithm. Combination therapy, including single pill combinations, is advised for high-risk patients to improve blood pressure control.
Area of Science:
- Cardiology
- Public Health
- Clinical Practice Guidelines
Background:
- Over 80% of the hypertensive population in China have uncontrolled blood pressure (BP), necessitating improved management strategies.
- Recent updates to US and European hypertension guidelines offer new insights for hypertension management.
- The 2018 Chinese hypertension guidelines were issued in 2019 after a three-year revision process.
Purpose of the Study:
- To summarize the key highlights and recommendations of the 2018 Chinese hypertension guidelines.
- To provide an overview of the updated hypertension management strategies in China.
- To inform physicians and practitioners on the latest evidence-based hypertension care.
Main Methods:
- The review focuses on the diagnostic criteria and treatment algorithms presented in the 2018 Chinese hypertension guidelines.
- Comparison with recent US and European guidelines regarding hypertension definition and treatment approaches.
- Analysis of recommended antihypertensive drug classes and combination therapy strategies.
Main Results:
- The Chinese guidelines retain the diagnostic threshold of ≥140/90 mmHg for hypertension, differing from the US guidelines.
- A new algorithm for antihypertensive treatment is introduced, integrating cardiovascular risk and BP levels.
- Five classes of antihypertensive drugs are recommended, with combination therapy, including single pill combinations (SPC), indicated for high-risk patients or those with grade 2 or 3 hypertension.
Conclusions:
- China continues to refine its hypertension management strategies to enhance BP control rates.
- The latest Chinese guidelines and expert consensus offer valuable guidance for healthcare professionals.
- Implementation of these guidelines is expected to improve the management of hypertension in China.
Background:
Blood pressure (BP) are uncontrolled in over 80% hypertensive population in China, indicating a compelling need for a pragmatic hypertension management strategy. The 2018 Chinese hypertension guidelines issued in 2019, after 3 years revision. During the periods, the latest United States (US) and European guidelines successively published, bringing new thoughts, wisdoms and schemes on hypertension management. This review aims to summarize the highlights of the new Chinese guidelines.
Main Text:
Despite the fact that the 2017 US hypertension guidelines changed hypertension definition from ≥140/90 mmHg to 130/80 mmHg, the Chinese hypertension guidelines did not follow suit, and maintained 140/90 mmHg as the cut-point of for diagnosis of hypertension. A combined, cardiovascular risks and BP levels-based antihypertensive treatment algorithm was introduced. Five classes of antihypertensive drugs, including β-blockers were recommended as initiation and maintenance of BP-lowering therapy. Initiating combination therapy, including single pill combination (SPC) was indicated in high-risk patients or those with grade 2 or 3 hypertension. For those with grade 1 hypertension (BP ≥ 140/90 mmHg), an initial low-dose antihypertensive drugs combination treatment could be considered.
Conclusions:
China has never stopped exploring the best strategy for improving hypertension control. Based on clinical evidence and expertise, the newest Chinese guidelines and expert consensus will be of help in guiding physicians and practitioners to provide better management of hypertension in China.
More Related Videos
Related Concept Videos
Hypertension I: Introduction
Hypertension V: Nursing Management
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension IV: Drug Therapy and Lifestyle Modifications
Hypertension II: Pathophysiology
Hypertension and Regulation of Blood Pressure

